Assembly of Nanocatalyst As a Noninvasive Tool for Breast Cancer Diagnosis and Immunotherapy Surveillance Designed by Visually Tracking Tumor-Derived Exosomal PD-L1-Reference-Cited by-同舟云学术

Assembly of Nanocatalyst As a Noninvasive Tool for Breast Cancer Diagnosis and Immunotherapy Surveillance Designed by Visually Tracking Tumor-Derived Exosomal PD-L1

Published:2022-12-25 Issue:2 Volume:5 Page:282-290
ISSN:2639-4979
Container-title:ACS Materials Letters
language:en
Short-container-title:ACS Materials Lett.

Author:

Shi Hai¹,Zeng Tianyu¹,Liu Yincheng²,Liang Qizhi³,Yang Fan¹,Liang Yan¹,Fu Ziyi¹,Li Wei¹,Li Genxi³⁴^ORCID,Yin Yongmei¹^ORCID

Affiliation:

1. Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P. R. China

2. Department of Breast Disease, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P. R. China

3. State Key Laboratory of Analytical Chemistry for Life Science, School of Life Sciences, Nanjing University, Nanjing 210023, P. R. China

4. Center for Molecular Recognition and Biosensing, School of Life Sciences, Shanghai University, Shanghai 200444, P. R. China

Funder

Ministry of Science and Technology of the People's Republic of China

?333 Project? of Jiangsu Province

Nanjing Medical University

Wu Jieping Medical Foundation

Postgraduate Research and Practice Innovation Program of Jiangsu Province

Collaborative innovation center for tumor individualization focuses on open topics

Key medical talents

China key research and development program precision medicine research

Publisher

American Chemical Society (ACS)

Subject

General Materials Science,Biomedical Engineering,General Chemical Engineering

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmaterialslett.2c01036

Reference44 articles.

1. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

2. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer

3. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

4. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

5. 1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis of a COF-on-MOF hybrid nanomaterial for enhanced colorimetric biosensing;Talanta;2024-07

2. Dual-Recognition-Mediated Autocatalytic Amplification Assay for the Subpopulations of PD-L1 Positive Extracellular Vesicle;Analytical Chemistry;2024-05-30